Associated Papers
An open-label, phase IB/II study of abemaciclib with paclitaxel for tumors with CDK4/6 pathway genomic alterations.
Kim KH et al.
Esmo Open, 2025
39874900 (PubMed )
Supplement: mmc1.xlsx › Mutation
PARP inhibitor therapy in patients with IDH1 mutated cholangiocarcinoma.
Mohan A et al.
The Oncologist, 2024
Paired comparisons of mutational profiles before and after brachytherapy in asian uveal melanoma patients.
Lee WS et al.
Scientific Reports, 2021
34545149 (PubMed )
Supplement: 41598_2021_98084_MOESM2_ESM.xlsx › Nonsynonymous_SNV_All_YUHS
Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets.
Chen YB et al.
Nature Communications, 2016
27713405 (PubMed )
Supplement: ncomms13131-s3.xlsx › All_mutations
Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinoma.
Piva F et al.
Oncotarget, 2015
26452128 (PubMed )
Supplement: oncotarget-06-32161-s002.xls › Predictions
Characterization of a carboxy-terminal BRCA1 interacting protein.
Wong AK et al.
Oncogene, 1998
Select a paper to view details